Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21287


Purpose:

This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.


Study summary:

The investigators propose to evaluate the feasibility of using a novel small molecule PET radiotracer, DCFPyL to target prostate cancer prostate-specific membrane antigen (PSMA). PSMA is a well studied cell surface marker of prostate cancer with increased expression associated with higher tumor grade and advanced metastatic tumors. More specifically it is associated with a higher Gleason score and there is evidence it can serve as a potential marker for prostate tumor carcinogenesis, progression and as a AR signaling surrogate marker of ADT response. This small molecule PET radiotracer specifically targeting an important prostate specific marker of AR signaling dynamics following ADT, tumor progression and metastatic potential warrants validation as an in-vivo non-invasive imaging biomarker for PSMA expression and prostate cancer detection.


Criteria:

Inclusion Criteria: - Men 18 years of age or greater with recently diagnosed prostate cancer with planned radiation and ADT. - Key inclusion criteria (the entire list of inclusion and exclusion criteria will appear later in section 4 of the protocol) - Newly diagnosed prostate cancer pathologically proven by prostate biopsy - Prostate biopsy histology grade ≥ Gleason 8-10 - Patients considered as candidates for and medically fit to undergo radiation and ADT - At least 10 days after most recent prostate biopsy Exclusion Criteria: - Prior pelvic external beam radiation therapy or brachytherapy - Chemotherapy for prostate cancer - Hormone deprivation therapy - Investigational therapy for prostate cancer - Hemorrhagic cystitis or active prostatitis


NCT ID:

NCT02420977


Primary Contact:

Principal Investigator
Theodore DeWeese, M.D.
The SKCCC at Johns Hopkins

Phuoc Tran, M.D., Ph.D.
Phone: (410) 614-3880
Email: tranp@jhmi.edu


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21287
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.